Current Report Filing (8-k)
November 25 2019 - 9:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): November 25, 2019
ADAMIS
PHARMACEUTICALS CORPORATION
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
11682
El Camino Real, Suite 300
San
Diego, CA
|
|
92130
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
|
|
|
|
|
|
|
Registrant’s
telephone number, including area code: (858) 997-2400
(Former
name or Former Address, if Changed Since Last Report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on
which registered
|
Common
Stock
|
|
ADMP
|
|
NASDAQ
Capital Market
|
On
November 25, 2019, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) issued a press
release announcing that after the close of U.S. markets on November 22, 2019, it received a Complete Response Letter
(“CRL”) from the U.S. Food & Drug Administration (“FDA”) regarding the Company’s New Drug
Application (“NDA”) for its ZIMHI™ high-dose naloxone injection product for the treatment of opioid
overdose. A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review of a file and
questions remain that preclude the approval of the NDA in its current form.
The
CRL stated that the FDA determined that it cannot approve the Company’s NDA in its present form.
The
Company is reviewing the CRL and plans to request a meeting with the FDA to discuss the CRL and the Company’s
response to the CRL. A copy of the Company’s press release is attached hereto as Exhibit 99.1 is incorporated into this
item by reference.
Item
9.01
|
Financial
Statements and Exhibits
|
Exhibit No.
|
Description
|
99.1
|
Press
Release dated November 25, 2019.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated: November 25, 2019
|
By:
|
/s/
Robert O. Hopkins
|
|
Name:
|
Robert O. Hopkins
|
|
Title:
|
Chief Financial
Officer
|